MindMed to Participate in March Investor Conferences
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) will participate in several investor conferences this March, showcasing its innovations in treating brain health disorders.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) will participate in several investor conferences this March, showcasing its innovations in treating brain health disorders. Key events include the 34th Annual Roth Conference on March 15, the Oppenheimer Virtual Healthcare Conference on March 17, and the Maxim Virtual Growth Conference from March 28-30. Each event will feature presentations focused on the company's advancements in psychiatry and neurology. A replay of the webcasts will be available on MindMed's website for 30 days post-presentation.
Details
News Market Reaction – MNMD
The recorded move for MNMD in the trading session of this news was +7.92%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
NEW YORK, March 9, 2022 /PRNewswire/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), a clinical-stage biopharmaceutical company developing novel products to treat brain health disorders, today announced that Robert Barrow, Chief Executive Officer and Director, will participate in the following upcoming investor conferences in March:
34th Annual Roth Conference
Format: Panel – Psychedelics: "Immunotherapy" for the Mind
Date: Tuesday, March 15 at 10:00 AM PST / 1:00 PM EST
Webcast Link: Click Here
Oppenheimer Virtual Annual Healthcare Conference
Format: Corporate Presentation
Date: Thursday, March 17 at 12:40 PM EST
Webcast Link: Click Here
Maxim Virtual Growth Conference
Format: Corporate Presentation
Date: March 28-30, 2022
Further Info: Click Here
A replay of the webcasts will be available in the "Investors" section of MindMed's website for 30 days following each of the presentations.
About MindMed
MindMed is a clinical-stage biopharmaceutical company developing novel products to treat brain health disorders, with a particular focus on psychiatry, addiction, pain and neurology. Our mission is to be the global leader in the development and delivery of treatments that unlock new opportunities to improve patient outcomes. We are developing a pipeline of innovative drug candidates, with and without acute perceptual effects, targeting the serotonin, dopamine and acetylcholine systems.
MindMed trades on the NASDAQ under the symbol MNMD and on the Canadian NEO Exchange under the symbol MMED.
View original content to download multimedia:https://www.prnewswire.com/news-releases/mindmed-to-participate-in-march-investor-conferences-301498744.html
SOURCE Mind Medicine (MindMed) Inc.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.